Exicure Inc (XCUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Exicure Inc (XCUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH375392D
  • |
  • Pages: 38
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Exicure Inc (Exicure), formerly AuraSense Therapeutics LLC is a biotechnology company that discovers, develops, and commercializes immunomodulatory and gene silencing drugs based on 3-dimensional spherical nucleic acid constructs. The company's technology portfolio includes SNA gene regulation platform and genetic analysis tools. Its pipeline spans SNA based therapeutics for the treatment of psoriasis, fibrosis, diabetic ulcers, bladder cancer, and inflammation. Exicure SNA's are also used as immunotherapeutic agents for the treatment of cancer and other infectious diseases. The company works in collaboration with various pharmaceutical and biotechnology companies for exploring its SNA platform application against multiple diseases. Exicure is headquartered in Skokie, Illinois, the US.

Exicure Inc (XCUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Exicure Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Exicure Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Exicure Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Exicure Secures Venture Funding 10

Exicure Raises USD14.8 Million Financing 11

AuraSense Therapeutics Raises USD4.4 Million in Extended Series C Financing 12

AuraSense Therapeutics Raises USD13.6 Million in Series C Financing 13

AuraSense Therapeutics Raises Funds Through Extended Series B Financing 14

Partnerships 15

Exicure Enters into Agreement with Ohio State University 15

Merger 16

Exicure and Max-1 Acquisition Merges in Reverse Merger Transaction 16

Licensing Agreements 17

Purdue Pharma Enters into Licensing Agreement with Exicure 17

Exicure Enters into Licensing Agreement with Northwestern University 18

Exicure Enters into Licensing Agreement with Northwestern University for SNA Technology 19

Equity Offering 20

Exicure Plans to Raise up to USD119.1 Million in Private Placement of Shares 20

Exicure Raises Additional USD11.2 Million in Private Placement of Shares 21

Exicure Raises USD20 Million in Private Placement 22

Exicure Inc - Key Competitors 23

Exicure Inc - Key Employees 24

Exicure Inc - Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Financial Announcements 26

Aug 06, 2018: Exicure provides update on corporate progress and second quarter 2018 financial results 26

May 15, 2018: Exicure Announces First Quarter 2018 Financial Results 28

Mar 09, 2018: Exicure Reports Full Year 2017 Financial Results And Corporate Progress 30

Nov 14, 2017: Exicure Reports Third Quarter 2017 Financial Results and Provides Business Update 32

Corporate Communications 34

Apr 20, 2018: Exicure Appoints Matthias Schroff As Chief Operating Officer 34

Clinical Trials 35

Jun 14, 2018: Exicure to Present Data at the Cure Spinal Muscular Atrophy Annual Conference in Dallas 35

Other Significant Developments 36

May 23, 2018: Exicure To Begin Trading on United States OTCQB Under the Symbol XCUR 36

May 27, 2017: Investors flock to exicure s IPO - Luye Pharma s strategy of investment in novel biopharmaceuticals receives optimistic outlook 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38

List of Figures

Exicure Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Exicure Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Exicure Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Exicure Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Exicure Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Exicure Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Exicure Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Exicure Secures Venture Funding 10

Exicure Raises USD14.8 Million Financing 11

AuraSense Therapeutics Raises USD4.4 Million in Extended Series C Financing 12

AuraSense Therapeutics Raises USD13.6 Million in Series C Financing 13

AuraSense Therapeutics Raises Funds Through Extended Series B Financing 14

Exicure Enters into Agreement with Ohio State University 15

Exicure and Max-1 Acquisition Merges in Reverse Merger Transaction 16

Purdue Pharma Enters into Licensing Agreement with Exicure 17

Exicure Enters into Licensing Agreement with Northwestern University 18

Exicure Enters into Licensing Agreement with Northwestern University for SNA Technology 19

Exicure Plans to Raise up to USD119.1 Million in Private Placement of Shares 20

Exicure Raises Additional USD11.2 Million in Private Placement of Shares 21

Exicure Raises USD20 Million in Private Placement 22

Exicure Inc, Key Competitors 23

Exicure Inc, Key Employees 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Exicure Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 17970
Site License
USD 500 INR 35940
Corporate User License
USD 750 INR 53910

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com